RxDoctor Payments Data

William Jones, MD

Family Medicine · Brookneal, VANPI 1366449704

Payments from drug & device makers

$3,665in general payments, 2019–2025

Across 127 payments — averaging $28.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$655
  • Amgen$313
  • Boehringer Ingelheim$260
  • GSK$241
  • AbbVie$226
  • plus $748 from 12 others

What the payments were for

  • Consulting fees$1755%
  • Speaking & faculty fees$501%
  • Food & beverage$3,44094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,665 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$89,597
Medicare patients
208
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide37$54,643
EliquisApixaban50$46,134
OzempicSemaglutide33$43,934
FarxigaDapagliflozin Propanediol39$35,436
JardianceEmpagliflozin30$32,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$32,157
TrulicityDulaglutide19$21,747
XareltoRivaroxaban15$12,232
EntrestoSacubitril/Valsartan15$9,733
LinzessLinaclotide12$9,643
SymbicortBudesonide/Formoterol Fumarate21$7,191
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,873
Novolog FlexpenInsulin Aspart13$2,623
Atorvastatin Calcium344$2,560
Albuterol Sulfate HfaAlbuterol Sulfate60$1,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$655$98,57770 claims
PfizerEliquis$96$46,13450 claims
AstraZenecaFarxiga, Symbicort$1,223$42,62760 claims
Boehringer IngelheimJardiance$260$32,46930 claims
GSKTrelegy Ellipta$241$32,15732 claims
Lilly USA, LLCTrulicity$143$21,74719 claims
AbbVieLinzess$226$9,64312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Brookneal

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →